Abstract | BACKGROUND: METHODS: RESULTS: The mean (+/-SE) event-free survival rate three years after the first randomization was significantly better among the 189 patients who were assigned to undergo transplantation than among the 190 patients assigned to receive continuation chemotherapy (34+/-4 percent vs. 22+/-4 percent, P=0.034). The event-free survival rate three years after the second randomization was significantly better among the 130 patients who were assigned to receive 13-cis-retinoic acid than among the 128 patients assigned to receive no further therapy (46+/-6 percent vs. 29+/-5 percent, P=0.027). CONCLUSIONS:
|
Authors | K K Matthay, J G Villablanca, R C Seeger, D O Stram, R E Harris, N K Ramsay, P Swift, H Shimada, C T Black, G M Brodeur, R B Gerbing, C P Reynolds |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 341
Issue 16
Pg. 1165-73
(Oct 14 1999)
ISSN: 0028-4793 [Print] United States |
PMID | 10519894
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Bone Marrow Transplantation
(adverse effects)
- Child
- Child, Preschool
- Combined Modality Therapy
- Disease-Free Survival
- Humans
- Infant
- Isotretinoin
(adverse effects, therapeutic use)
- Life Tables
- Neuroblastoma
(drug therapy, mortality, radiotherapy, therapy)
- Prospective Studies
- Risk
- Transplantation Conditioning
- Whole-Body Irradiation
|